Oncolytics Builds a 20-Year Patent Fortress for Its Cancer Immunotherapy

SAN DIEGO, CA – June 16, 2026 – In the high-stakes world of biotechnology, a promising drug is only as valuable as the intellectual property that protects it. Oncolytics Biotech® Inc. took a monumental step today in securing the future of its lead drug candidate, pelareorep, announcing the issuance of a new U.S. patent that shields its commercial manufacturing process from competitors until 2044. While the news sent the company’s stock (NASDAQ: ONCY) up 11%, the real story is a masterclass in strategic de-risking, transforming a complex biological process into a defensible, long-term asset.

For investors and industry watchers, the announcement is more than a standard IP update; it's a critical success signal. It confirms that Oncolytics not only has a promising investigational therapy but also a protected, scalable method to produce it. This move addresses a fundamental, and often overlooked, hurdle in drug development: the transition from lab-scale batches to consistent, commercial-grade manufacturing. By locking down the “how,” Oncolytics has significantly strengthened the commercial case for pelareorep as it advances toward potential registration.

The Moat Around Manufacturing

In biotechnology, patents covering a drug's use or formulation are common. However, a patent protecting the manufacturing process itself provides a different, arguably more robust, layer of defense. It creates a formidable barrier to entry for potential biosimilar competitors, who would need to engineer a completely different, non-infringing method to produce the therapy—a complex and costly endeavor for a biologic agent like pelareorep.

This new patent is designed to protect the company’s ability to consistently produce pelareorep at commercial scale, a crucial factor as the therapy progresses through late-stage clinical trials. “Building a strong intellectual property estate around pelareorep is an important part of our strategy as we advance the program toward potential registration and commercialization,” said Jared Kelly, Chief Executive Officer of Oncolytics, in the company's statement. “This newly issued patent strengthens our protection around the manufacturing of pelareorep and supports our ability to produce the product at commercial scale.”

The market’s positive reaction underscores the importance of this milestone. While Oncolytics remains a clinical-stage company with modest revenue, this patent provides a tangible asset that bolsters its valuation and enhances its appeal for potential partnerships or licensing deals. For a company navigating the capital-intensive path to drug approval, demonstrating this level of strategic foresight can be as crucial as positive clinical data.

The Science Driving the Strategy

The value of this manufacturing patent is intrinsically tied to the clinical promise of pelareorep itself. The investigational therapy is an immunotherapeutic agent designed to solve a core challenge in oncology: turning immunologically “cold” tumors, which are invisible to the immune system, into “hot” tumors that can be recognized and attacked. Delivered intravenously, pelareorep activates the body's innate and adaptive immune responses, effectively priming the tumor microenvironment for destruction.

The clinical data amassed so far is compelling. In notoriously difficult-to-treat cancers, pelareorep has shown significant potential:

• Pancreatic Cancer: In a notoriously lethal disease, pooled data from two studies in first-line metastatic pancreatic cancer showed a two-year overall survival rate of 21.9% for patients treated with a pelareorep-based regimen, more than double the historical benchmark of 9.2%. These results helped earn the therapy a Fast Track designation from the FDA for this indication.

• Metastatic Breast Cancer: In two randomized Phase 2 studies, adding pelareorep to standard-of-care chemotherapy extended median overall survival by more than 10 months in patients with HR+/HER2- metastatic breast cancer.

• Colorectal Cancer: Pelareorep also holds Fast Track designation for KRAS-mutant metastatic colorectal cancer. Data from the REO 022 trial showed impressive results, with a median overall survival of 27.0 months, far exceeding historical benchmarks. Oncolytics is now in active discussions with the FDA regarding a potential accelerated approval pathway.

These promising results across multiple cancer types highlight why securing the drug’s long-term commercial viability is a top priority. With a well-understood safety profile across more than 1,100 patients, the primary challenges are now regulatory approval and market access—both of which are buttressed by a strong IP foundation.

A Multi-Layered Patent Fortress

Today’s announcement is a cornerstone of a much broader and more ambitious intellectual property strategy. Oncolytics is not just building a wall; it’s constructing a fortress. The company confirmed that a previously filed method-of-use patent application remains under review. If issued, it would provide protection for pelareorep’s use as an immunotherapy into 2046, extending the shield two years beyond the new manufacturing patent.

Furthermore, the company plans to file additional patent applications this year to cover new therapeutic applications, treatment settings, and combination approaches. This forward-looking strategy aims to create overlapping layers of protection that will cover pelareorep from every angle—how it's made, how it's used, and what it's used with—maximizing its value and securing its market exclusivity for decades to come.

This aggressive IP posture is essential in the competitive oncolytic virus therapy market, which is projected to grow into a multi-billion dollar industry. With Amgen’s Imlygic being the only FDA-approved therapy in the space, a huge opportunity exists for new entrants. By methodically checking the boxes of clinical efficacy, regulatory engagement, and now, manufacturing protection, Oncolytics is positioning pelareorep not just as a scientific breakthrough, but as a commercially sound investment. While the journey through final clinical trials and regulatory review is never without risk, securing the means of production until 2044 is a powerful declaration that the company is preparing to go the distance.